Law360 (June 19, 2019, 5:00 PM EDT) -- Venture-backed Stoke Therapeutics Inc., a biotechnology firm developing therapies for genetic diseases, went public Wednesday after raising $142 million in an upsized initial public offering, steered by Fenwick & West LLP and underwriters' counsel Davis Polk & Wardwell LLP.
Bedford, Massachusetts-based Stoke sold 7.9 million shares at $18 each — above its projected range of $14 to $16 — late on Tuesday. Stoke originally planned to sell 6.7 million shares. Shares were scheduled to begin trading Wednesday on the Nasdaq under the symbol "STOK."
Stoke told regulators it will spend IPO proceeds to develop a lead drug candidate designed to treat Dravet syndrome,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!